- Home
- BROS vs MRNA Comparison
BROS vs MRNA Comparison
Compare BROS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROS
- MRNA
- Stock Information
- Founded
- BROS 1992
- MRNA 2010
- Country
- BROS United States
- MRNA United States
- Employees
- BROS N/A
- MRNA N/A
- Industry
- BROS Restaurants
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BROS Consumer Discretionary
- MRNA Health Care
- Exchange
- BROS Nasdaq
- MRNA Nasdaq
- Market Cap
- BROS 9.1B
- MRNA 10.9B
- IPO Year
- BROS 2021
- MRNA 2018
- Fundamental
- Price
- BROS $64.59
- MRNA $23.51
- Analyst Decision
- BROS Strong Buy
- MRNA Hold
- Analyst Count
- BROS 18
- MRNA 19
- Target Price
- BROS $81.00
- MRNA $43.50
- AVG Volume (30 Days)
- BROS 3.3M
- MRNA 11.1M
- Earning Date
- BROS 11-05-2025
- MRNA 11-06-2025
- Dividend Yield
- BROS N/A
- MRNA N/A
- EPS Growth
- BROS 75.89
- MRNA N/A
- EPS
- BROS 0.48
- MRNA N/A
- Revenue
- BROS $1,451,963,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- BROS $27.79
- MRNA N/A
- Revenue Next Year
- BROS $24.80
- MRNA $10.17
- P/E Ratio
- BROS $134.69
- MRNA N/A
- Revenue Growth
- BROS 29.80
- MRNA N/A
- 52 Week Low
- BROS $30.49
- MRNA $23.15
- 52 Week High
- BROS $86.88
- MRNA $75.37
- Technical
- Relative Strength Index (RSI)
- BROS 45.42
- MRNA 36.83
- Support Level
- BROS $63.67
- MRNA $24.21
- Resistance Level
- BROS $66.77
- MRNA $25.90
- Average True Range (ATR)
- BROS 3.04
- MRNA 1.19
- MACD
- BROS -0.77
- MRNA 0.08
- Stochastic Oscillator
- BROS 8.38
- MRNA 8.17
About BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.